[Fundamental and clinical studies on cefpimizole in the field of obstetrics and gynecology].

The findings from fundamental and clinical studies on cefpimizole (AC-1370) in the treatment of infections in obstetrics and gynecology are reported. We investigated the transfer of AC-1370 into female genital tissues of 6 patients and the transfer of the drug into the pelvic dead space exudate in 9 patients by means of determining its concentrations in the tissues 90 to 210 minutes after the end of intravenous drip infusion of the drug over 1 hour. The mean concentration was 13.06 micrograms/g for the oviduct, 16.50 micrograms/g for the ovary, 16.50 micrograms/g for the endometrium, 14.92 micrograms/g for the myometrium, 16.58 micrograms/g for the uterine cervix, 17.75 micrograms/g for the portio vaginalis, 10.46 micrograms/ml for the uterine arterial serum and 9.91 micrograms/ml for the antecubital venous serum. The drug proved to be well transferred into the pelvic dead space exudate; it reached a peak of mean 2 hours after the end of the intravenous drip infusion of the drug over 1 hour, then decreased steadily, and was found to be a mean of 16.7 micrograms/ml even 8 hours after the end of the intravenous drip infusion. Four patients with infections in obstetrics and gynecology were then treated with AC-1370. Three out of the 4 patients responded to the treatment, while the response of another patient was unknown. None of the 4 patients showed any side effects of the drug or any abnormalities in laboratory findings.